Product Description
NX-0255 is a highly potent CBL-B inhibitor (CBL-Bi), significantly increases TIL growth with a favorable phenotype at research scale expansion. (Sourced from: https://ir.nurixtx.com/static-files/8d5627d9-4784-4cf2-a73c-1e00596e31b7)
Mechanisms of Action: CBL-B Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nurix Therapeutics
Company Location: SAN FRANCISCO CA 94158
Company CEO: Arthur T. Sands
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|